drugset / Trial / NCT05328154
MAGnesium Effect With ANtiosteoporotic Drugs
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized pilot clinical trial to demonstrate superiority of bisphosphonate-magnesium combination over bisphosphonates alone in postmenopausal osteoporosis in slowing bone remodeling as assessed by C-terminal telopeptide of bone collagen type 1 (CTX) dosage.
Timeline
- Start
- 2022-06-28
- Primary completion
- 2024-12-19
- Completion
- 2024-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Magnesium carbonate | Small molecule | 200 mg | Oral |
| Comparator | Zoledronic acid | Other / unclassified | 5 mg | Intravenous |